http://debianws.lexgopc.com/wiki143/index.php?action=history&feed=atom&title=Agent_studyAgent study - Revision history2026-05-03T22:48:39ZRevision history for this page on the wikiMediaWiki 1.43.1http://debianws.lexgopc.com/wiki143/index.php?title=Agent_study&diff=5099214&oldid=previmported>OAbot: Open access bot: url-access updated in citation with #oabot.2025-05-27T20:42:39Z<p><a href="https://en.wikipedia.org/wiki/OABOT" class="extiw" title="wikipedia:OABOT">Open access bot</a>: url-access updated in citation with #oabot.</p>
<p><b>New page</b></p><div>An '''agent study''' is a part of a [[clinical trial]] that tests the [[chemotherapy|chemotherapeutic]] properties of a specific substance. More specifically, an agent study is used to detect whether or not a substance can prevent or inhibit [[cancer]].<ref>[http://www.stjude.org/glossary glossary<!-- Bot generated title -->] {{webarchive |url=https://web.archive.org/web/20070718061451/http://www.stjude.org/glossary |date=July 18, 2007 }}</ref> In a clinical trial, researchers perform multiple studies in order to test the potential of new cancer drugs. An agent study helps determine the potential of a substance to inhibit cancer, before more studies are done in order to further knowledge of this potential.<br />
<br />
==Cytotoxic vs. Cytostatic Agents==<br />
Agent studies are used to determine whether a substance exhibits [[cytotoxicity]] or [[cytostasis]]. A cytotoxic agent will shrink a tumor, while, a cytostatic agent slows or stops tumor growth and [[metastases]]. It is important to determine which of these effects an agent poses so that a proper clinical trial can be designed. For example, a study with a cytotoxic agent will look for tumor shrinkage vs. dose. It is much harder to develop a clinical trial for a cytostatic agent.<ref name='American Society of Clinical Oncology 2001'>{{cite journal | title = Clinical Trial Designs for Cytostatic Agents: Are New Approaches Needed? | journal = Journal of Clinical Oncology | date = 2001-01-01 | first = Edward L. | last = Korn |author2=Susand G. Arbuck|author3=James M. Pluda|author4=Richard Simon|author5=Richard S. Kaplan|author6=Michaela C. Christian | volume = 19 | issue = 1 | pages = 265–272| pmid = 11134222| url = http://jco.ascopubs.org/content/19/1/265.full | accessdate = 2013-11-25 | doi=10.1200/jco.2001.19.1.265| url-access = subscription }}</ref><br />
<br />
==Phase I Clinical Trials==<br />
Phase I trials are used to determine the [[maximum tolerated dose]] of an agent. This dose is then used in the Phase II trials. Maximum tolerated dose is based on the measured toxicity in cytotoxic agents. Cytostatic agents have been demonstrated to show biologic effects while also being nontoxic. It is recommended that cytostatic agent trials determine toxicity as well as evaluation of a biologic end point in response to different doses.<ref name="American Society of Clinical Oncology 2001"/><br />
<br />
Synonym:<br />
Chemoprevention study<br />
<br />
==References==<br />
{{reflist}}<br />
<br />
==See also==<br />
*[[Cancer]]<br />
*[[Clinical trial]]<br />
<br />
[[Category:Cancer research]]<br />
<br />
<br />
{{Pharma-stub}}</div>imported>OAbot